<div id="readability-page-1" class="page"><div>
    <div>
        <figure id="media-100000005759316" data-media-action="modal" itemprop="associatedMedia" itemscope="" itemid="https://static01.nyt.com/images/2018/02/24/science/24drug1-print/23DRUG1-master768.jpg" itemtype="http://schema.org/ImageObject" aria-label="media" role="group">
    <span>Photo</span>
    <div>
            <img src="https://static01.nyt.com/images/2018/02/24/science/24drug1-print/23DRUG1-master768.jpg" alt="" data-mediaviewer-src="https://static01.nyt.com/images/2018/02/24/science/24drug1-print/23DRUG1-superJumbo.jpg" data-mediaviewer-caption="A Teva Pharmaceutical drug manufacturing facility in Jerusalem. The company announced earlier this month it would sell a generic version of the drug Syprine at a lower price, but it&amp;rsquo;s hardly a bargain." data-mediaviewer-credit="Thomas Koehler/Photothek, via Getty Images" itemprop="url" itemid="https://static01.nyt.com/images/2018/02/24/science/24drug1-print/23DRUG1-master768.jpg">
            <meta itemprop="height" content="512">
            <meta itemprop="width" content="768">
    </div>
        <figcaption itemprop="caption description">
                <span>A Teva Pharmaceutical drug manufacturing facility in Jerusalem. The company announced earlier this month it would sell a generic version of the drug Syprine at a lower price, but it’s hardly a bargain.</span>
                        <span itemprop="copyrightHolder">
            <span>Credit</span>
            Thomas Koehler/Photothek, via Getty Images        </span>
            </figcaption>
    </figure>

<p data-para-count="252" data-total-count="252" _translation="当最近Teva Pharmaceuticals宣布它将开始销售Syprine仿制药 - 一种在20世纪60年代发明的昂贵药物时 - 对于服用价格暴涨的老药物的人来说，这个消息似乎是一个值得欢迎的发展。">When Teva Pharmaceuticals announced recently that it would begin selling a copycat version of Syprine — an expensive drug invented in the 1960s — the news seemed like a welcome development for people taking old drugs that have skyrocketed in price.</p><p data-para-count="523" data-total-count="775" _translation="在Valeant Pharmaceuticals International将该药的价格从五年前的652美元提高到2015年的21,267美元后，Syprine 治疗了一种罕见的称为威尔逊病的疾病。除了图灵药业的Martin Shkreli和Mylan（EpiPen的制造商）的Heather Bresch等制药公司的类似做法外，这个故事还引发了关于处方药高成本的全国对话，更不用说国会调查和联邦调查了。">Syprine, which treats a rare condition known as Wilson disease, <a href="https://www.nytimes.com/2015/10/05/business/valeants-drug-price-strategy-enriches-it-but-infuriates-patients-and-lawmakers.html">gained notoriety after Valeant Pharmaceuticals International raised the price of the drug</a> to $21,267 in 2015 from $652 just five years earlier. Along with similar practices by pharmaceutical executives like <a href="https://www.nytimes.com/2015/09/21/business/a-huge-overnight-increase-in-a-drugs-price-raises-protests.html?action=click&amp;contentCollection=Business%20Day&amp;module=RelatedCoverage&amp;region=Marginalia&amp;pgtype=article">Martin Shkreli of Turing Pharmaceuticals</a> and <a href="https://www.nytimes.com/2016/08/27/business/painted-as-a-villain-mylans-chief-says-shes-no-such-thing.html">Heather Bresch of Mylan</a> (the maker of the EpiPen), the story helped spark a national conversation about the high cost of prescription drugs, not to mention Congressional inquiries and federal investigations.</p><p data-para-count="195" data-total-count="970" _translation="在推广其 “Syprine”的“低成本”替代方案时，Teva执行官在新闻稿中吹嘘说，该产品“体现了Teva致力于为需要帮助的患者群体提供服务”。"><a href="http://www.tevapharm.com/news/teva_announces_launch_of_a_generic_version_of_syprine_in_the_united_states_02_18.aspx">In promoting its</a> “lower-cost” alternative to Syprine, a Teva executive boasted in a news release that the product “illustrates Teva’s commitment to serving patient populations in need.”</p><p data-para-count="270" data-total-count="1240" _translation="Elsevier公司的黄金标准药物数据库显示，这款产品没有提及的价格是：Teva的新型仿制药每瓶100粒的价格为18,375美元。这是Syprine在2010年花费的28倍，而且几乎没有许多病人等待的折扣。">What the release didn’t mention was the price: Teva’s new generic will cost $18,375 for a bottle of 100 pills, <a href="https://www.elsevier.com/solutions/drug-database">according to Elsevier’s Gold Standard Drug Database.</a> That’s 28 times what Syprine cost in 2010, and hardly the discount many patients were waiting for.</p>
<p data-para-count="217" data-total-count="1457" id="story-continues-1" _translation="在Valeant令人震惊的价格上涨引发公众愤怒之后的近三年，Syprine的故事突出表明，一旦将它们设定在平流层水平后，降低药品价格是多么的困难。">Nearly three years after Valeant’s egregious price increases ignited public outrage, the story of Syprine highlights just how hard it can be to bring down drug prices once they’ve been set at stratospheric levels.</p>        <a href="#story-continues-2">Continue reading the main story</a>
    </div><!-- close story-body -->
    <!-- close supplemental -->
</div><div>
    <div>
        <p data-para-count="377" data-total-count="1834" id="story-continues-3" _translation="尽管美国食品和药物管理局为鼓励没有通用替代品的药物争取更多的竞争，但只要没有显着的竞争，像Teva这样的公司仍然会按市场承受的那样收费。甚至像Valeant这样受到严厉批评的公司，往往可以通过援助计划消除消费者的不满。">Despite efforts by the Food and Drug Administration to encourage more competition for drugs that have no generic alternatives, companies like Teva will still charge as much as the market will bear as long as there is no significant competition. And even companies that come under intense criticism, like Valeant, can often neutralize consumer upset through assistance programs.</p><p data-para-count="195" data-total-count="2029" _translation="虽然这些可以降低患者的自付费用，但这些计划将保险费用保留在账单的大部分中，然后通过更高的保费和免赔额将这些费用转嫁给消费者。">While those can lower out-of-pocket costs for patients, the programs stick insurers with the bulk of the bill, which in turn can be passed on to consumers through higher premiums and deductibles.</p><p data-para-count="192" data-total-count="2221" _translation="现年59岁的Jay Copeland一直服用Syprine十年来治疗威尔逊病，这种病导致铜在体内积聚，如果不治疗会导致器官和神经损伤。">Jay Copeland, 59, has been taking Syprine for a decade to treat Wilson disease, a condition that causes copper to build up in the body, leading to organ and neurological damage if not treated.</p><p data-para-count="361" data-total-count="2582" _translation="“科普兰先生说，通用价格”令人难以置信的惩罚性“，他说，他的雇主的保险使他免受大部分药物的损失，但他担心如果他失去了工作会发生什么。他表示，Teva稍低的价格“对我来说，如果我能够支付巨额实付费用，这对我来说几乎没有什么影响。”">Calling the generic price “incredibly punitive,” Mr. Copeland said his employer’s insurance shields him from most of the drug’s cost, but he worries what would happen if he were to lose his job. Teva’s slightly lower price, he said, “would make relatively little difference to me if I were put in the position to pay enormous out-of-pocket costs.”</p><p data-para-count="264" data-total-count="2846" _translation="为了鼓励更为普通的竞争，FDA最近公布了一份非专利药物清单，该清单没有竞争，并且清除了通用申请的积压。但正如Syprine案例所显示的那样，通常并不像添加一个通用竞争对手那么简单。">To encourage more generic competition, the F.D.A. recently published a list of off-patent drugs that have no competition and cleared a backlog of generic applications. But as the Syprine case shows, it often isn’t as simple as adding a single generic competitor.</p><p data-para-count="208" data-total-count="3054" _translation="“总的来说，仿制药在有多个参与者的情况下工作，”Wells Fargo的分析师David Maris说，他本周撰写了关于Teva的普通Syprine价格的文章。“如果没有，你会得到这个。”">“By and large, generics work when there are multiple players,” said David Maris, an analyst at Wells Fargo who wrote this week about Teva’s generic Syprine price. “When there’s not, you get this.”</p><p data-para-count="345" data-total-count="3399" _translation="如果只有少数参与者，并且如同威尔逊病一样，这些药物会治疗一小部分患者，那么这些公司将尽可能多地获得利润。根据数据研究公司IQVIA的数据，2017年前三季度仅有5,226张处方药被用于Syprine，也被称为盐酸曲恩汀。">If there are just a few players and if the drug treats a small group of patients, as is the case with Wilson disease, the companies will try to make as much profit as they can. Just 5,226 prescriptions were filled for Syprine, also known as trientine hydrochloride, in the first three quarters of 2017, according to the data research firm IQVIA.</p>
<p data-para-count="255" data-total-count="3654" id="story-continues-4" _translation="根据威尔逊疾病协会科学事务副总裁玛丽·格雷珀的说法，威尔逊病被认为在美国有8000到10000人之间影响，有些病人服用其他药物。">Wilson disease is believed to affect between 8,000 and 10,000 people in the United States, and some with the condition take other drugs, according to Mary Graper, the vice president of scientific affairs at the Wilson Disease Association, a patient group.</p><p data-para-count="266" data-total-count="3920" _translation="“通用公司以营利为目的的公司，也和让他们在定价他们认为市场的承受能力的产品，这并不奇怪我，”亚伦S. Kesselheim博士，哈佛大学医学院副教授说，谁拥有研究药物价格。">“Generic companies are for-profit companies, too, and so it’s not surprising to me that they price the product at what they think the market will bear,” said Dr. Aaron S. Kesselheim, an associate professor at Harvard Medical School <a href="http://www.nejm.org/doi/full/10.1056/NEJMc1711899">who has studied </a>drug prices.</p><figure id="media-100000005759318" data-media-action="modal" itemprop="associatedMedia" itemscope="" itemid="https://static01.nyt.com/images/2018/02/23/science/23DRUG2/23DRUG2-master675.jpg" itemtype="http://schema.org/ImageObject" aria-label="media" role="group">
    <span>Photo</span>
    <div>
            <img src="https://static01.nyt.com/images/2018/02/23/science/23DRUG2/23DRUG2-master675.jpg" alt="" data-mediaviewer-src="https://static01.nyt.com/images/2018/02/23/science/23DRUG2/23DRUG2-superJumbo.jpg" data-mediaviewer-caption="J. Michael Pearson, center, the chief executive of Valeant Pharmaceuticals International, at a senate hearing in April 2016. Valeant gained notoriety after raising the price of the drug Syprine from $652 to more than $21,000." data-mediaviewer-credit="Drew Angerer for The New York Times" itemprop="url" itemid="https://static01.nyt.com/images/2018/02/23/science/23DRUG2/23DRUG2-master675.jpg">
            <meta itemprop="height" content="450">
            <meta itemprop="width" content="675">
    </div>
        <figcaption itemprop="caption description">
                <span>J. Michael Pearson, center, the chief executive of Valeant Pharmaceuticals International, at a senate hearing in April 2016. Valeant gained notoriety after raising the price of the drug Syprine from $652 to more than $21,000.</span>
                        <span itemprop="copyrightHolder">
            <span>Credit</span>
            Drew Angerer for The New York Times        </span>
            </figcaption>
    </figure>
<p data-para-count="239" data-total-count="4159" _translation="Teva的一位发言人拒绝评论它如何设定价格，但表示公司考虑了一系列因素。“如果有更多的竞争和充足的供应，定价将继续下降，”发言人Kaelan Hollon说。">A spokeswoman for Teva declined to comment on how it set its price, but said the company considers a range of factors. “If there is more competition and ample supply, pricing will continue to fall,” said the spokeswoman, Kaelan Hollon.</p><p data-para-count="350" data-total-count="4509" _translation="自称为世界领先仿制药制造商的Teva 公司近年来一直面临管理混乱，销售领先名牌药物的失败，以及 - 与许多常用仿制药的价格下跌 - 扭曲的局面。去年12月，它宣布进行重大调整，包括削减25％的劳动力。">Teva, <a href="http://www.tevapharm.com/our_products/generic_products/">which calls itself the world’s leading manufacturer</a> of generic drugs, has struggled in recent years with management turmoil, lost sales of a leading brand-name drug, and — in a twist — <a href="https://www.nytimes.com/2017/08/08/health/generic-drugs-prices-falling.html">with the falling prices of many commonly used generic drugs</a>. <a href="https://www.nytimes.com/2017/12/14/business/dealbook/teva-pharmaceuticals-generic.html">In December, it announced a major reshaping</a>, including cutting 25 percent of its work force.</p><p data-para-count="236" data-total-count="4745" _translation="威尔逊病患者一直在注意普通Syprine的到来，但Teva的声明令他们吃惊，Graper女士说。“我们不知道该期待什么，但我个人希望有更多的折扣。”">Patients with Wilson disease had been watching for the arrival of a generic Syprine, but Teva’s announcement took them by surprise, Ms. Graper said. "We had no idea what to expect, but I had personally hoped for more of a discount.”</p>

<p data-para-count="387" data-total-count="5132" _translation="Valeant不甘示弱地跟随了Teva的举动，发布了自己的“授权”仿制Syprine。一些名牌制药商希望与仿制药制造商直接竞争，而不降低其名牌产品的价格，这是一种常见的策略，一些病人仍然喜欢。根据Elsevier的说法，Valeant授权的仿制药销售价格为19,119美元。">Not to be outdone, Valeant followed Teva’s move with the release of its own “authorized” generic of Syprine. It’s a common tactic by brand-name drugmakers who want to compete directly with generic manufacturers without lowering the price of their brand-name product, which some patients continue to prefer. Valeant’s authorized generic sells for $19,119, according to Elsevier.</p><p data-para-count="188" data-total-count="5320" _translation="Valeant发言人Lainie Keller表示，其通用名单的价格并未反映该公司与买家谈判的折扣，尽管她不会透露这些折扣。">Lainie Keller, a spokeswoman for Valeant, said the list price for its generic did not reflect discounts the company negotiates with buyers, although she would not disclose those discounts.</p><p data-para-count="243" data-total-count="5563" _translation="她表示，Valeant的耐心援助计划最近得到了改善，以确保私人保险患者每月只需支付约5美元。没有保险的人可以免费获得药物，只要他们符合一定的收入要求。">She said Valeant’s patient assistance programs have recently been improved to ensure that privately insured patients only pay about $5 a month. Those without insurance can get the medication for free if they meet certain income requirements.</p><p data-para-count="383" data-total-count="5946" _translation="瓦伦坦曾经是华尔街的最爱，通过购买旧的非专利药物如Syprine，大幅提高价格以及在研发上投入很少而使投资者感到高兴。这在2015年发生了变化，当时有人提出这个策略对患者产生的影响，以及该公司的财务实践及其与邮购药店的关系。">Valeant was once a Wall Street favorite that kept investors happy by buying up old, off-patent drugs like Syprine, sharply raising their prices, and investing little in research and development. That changed in 2015, when questions were raised about the impact this strategy was having on patients, and about the company’s financial practices and its ties to a mail-order pharmacy.</p>
<p data-para-count="173" data-total-count="6119" id="story-continues-5" _translation="国会和联邦调查公司的做法随之而来，导致股票暴跌，行政长官和主要投资者离职。">Congressional and federal investigations into the company’s practices followed, <a href="https://www.nytimes.com/2016/03/22/business/valeant-ackman-pearson-earnings.html">leading to a plummeting stock and the departure of the chief executive</a> and major investors.</p><p data-para-count="265" data-total-count="6384" _translation="Graper女士接受了Valeant和Teva的捐款，确认Valeant的患者援助计划已经改善，因为她的小组成员在参议院之前就公司的价格上涨如何导致他们停止服用药物作证。">Ms. Graper, whose group accepts donations from Valeant and Teva, confirmed that Valeant’s patient assistance program has improved since <a href="https://www.nytimes.com/2016/04/28/business/valeant-pearson-ackman-hearing-congress-drug-prices.html">members of her group testified before the Senate</a> about how the company’s price increases led them to stop taking their drugs.</p><p data-para-count="251" data-total-count="6635" _translation="这些行业援助计划本身受到审查 - 包括Valeant管理的计划 - 因为它们帮助提高了高昂的药物价格的可口性，减轻了患者自付的负担，同时让保险公司支付剩余的费用。">Such industry assistance programs have themselves come under scrutiny — <a href="https://democrats-oversight.house.gov/sites/democrats.oversight.house.gov/files/documents/Memo%20on%20Valeant%20Documents0.pdf">including ones run by Valeant</a> — because they have helped make high drug prices more palatable, easing patients’ out-of-pocket burdens while leaving insurers to pay the rest.</p><p data-para-count="180" data-total-count="6815" _translation="Graper女士表示希望，如果其他仿制药竞争者进入市场，价格将继续下跌。“我认为我们必须等待，看看这两个地方在哪里，”她说。">Ms. Graper expressed hope that if other generic competitors enter the market, the price will continue to fall. “I think we have to wait and see where these two land,” she said.</p><p data-para-count="231" data-total-count="7046" _translation="她和其他人表示，他们感到沮丧的是，尽管国会听证会，政府调查和政治家的承诺乱七八糟，许多引起初步愤慨的药物的价格仍然一如既往地高。">She and others said they were frustrated that despite a flurry of Congressional hearings, government investigations and promises by politicians, the price of many of the drugs that stoked the initial outrage remain as high as ever.</p><p data-para-count="236" data-total-count="7282" _translation="除了Syprine外，用于治疗严重寄生虫感染的老药Daraprim在Shkreli先生成为社交媒体恶棍之后两年内仍然是750美元的一颗药丸，因为他在价格从13.50美元一夜之间将价格提高。">In addition to Syprine, Daraprim, an old drug used to treat a serious parasitic infection, is still $750 a pill more than two years after Mr. Shkreli <a href="https://www.nytimes.com/2017/06/22/business/dealbook/martin-shkreli-pharma-bro-drug-prices.html">became a social media villain</a> for his role in raising the price overnight from $13.50.</p><p data-para-count="285" data-total-count="7567" _translation="EpiPen的成本是该趋势的一个例外。为响应EpiPen的价格（每包价格高达600美元），Mylan推出了一种更便宜的授权仿制药。现在可以在许多药店以约300美元的价格购买一盒EpiPens 。">The cost of the EpiPen is an exception to the trend. In response to the outcry over the EpiPen’s price, which reached about $600 at its height for a pack of two, <a href="https://www.nytimes.com/2016/08/30/business/mylan-generic-epipen.html">Mylan came out with a cheaper, authorized generic</a>. A pack of EpiPens <a href="https://www.goodrx.com/epipen?gclid=EAIaIQobChMIu5qch8O62QIVVbjACh0QKgxPEAAYASAAEgLTsPD_BwE">can now be bought for about $300 at many pharmacies</a>.</p><p data-para-count="183" data-total-count="7750" _translation="“我本来希望会有一些事情发生，政治家们会采取一些行动，但显然发生的事情并不多，”科普兰先生说。“这全都令人沮丧。”">“I had hoped that something would come of it, that the politicians would take some action, but obviously not much has happened,” Mr. Copeland said. “It’s all disheartening.”</p>        <a href="#whats-next">Continue reading the main story</a>
    </div><!-- close story-body -->
    <!-- close supplemental -->
</div></div>